Core Viewpoint - The stock market, represented by the S&P 500 index, has declined by 5.4% year-to-date as of March 24, indicating a broader downturn affecting many companies' stocks, which in turn enhances the dividend yield for dividend-paying stocks [1] Group 1: Investment Recommendation - The Schwab U.S. Dividend Equity ETF (SCHD) is recommended for long-term investment, suitable for various investment amounts ranging from $10,000 to $100,000 [2] - The ETF offers a dividend yield of 3.3%, significantly higher than the S&P 500's yield of 1.1%, providing both price appreciation and dividend income [2] - The ETF has shown strong performance with average annual gains of 12.90% over the past 3 years, 8.92% over the past 5 years, and 12.36% over the past 10 years [3] Group 2: ETF Composition and Holdings - The Schwab U.S. Dividend Equity ETF tracks an index of approximately 100 healthy dividend-paying companies, providing diversified exposure [3] - The top 10 holdings in the ETF include major companies such as Chevron (5.31% yield), Verizon Communications (5.56% yield), and Coca-Cola (2.76% yield), among others [3] - This ETF is positioned as a robust investment option, likely to continue paying dividends even during market downturns, making it a reliable choice for passive income [3]

Group 1 - The Rosen Law Firm is reminding purchasers of common stock of Ultragenyx Pharmaceutical Inc. about the lead plaintiff deadline for a class action lawsuit, which is set for April 6, 2026 [1][3] - Investors who purchased Ultragenyx common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm directly [3][7] Group 2 - The lawsuit alleges that Ultragenyx provided misleading information regarding the expected results of its Phase III studies for setrusumab, which is intended for treating Osteogenesis Imperfecta [5] - Defendants are accused of making overly positive statements about setrusumab's efficacy while concealing material adverse facts, leading to artificially inflated stock prices [6] - The lawsuit claims that the true state of setrusumab's potential was misrepresented, causing investors to suffer damages when the actual details became public [6]

NYMOX Provides Recent Updates <!-- Twitter Tags --> <!-- Facebook Tags --> <!-- Injecting site-wide to the head --> <!-- End Injecting site-wide to the head --><!-- Inject secured cdn script --> <!-- ========= Meta Tags ========= --> <!-- PWA settings --> <!-- Add manifest --> <!-- End PWA settings --> <!--Add favorites icons--><!-- End favorite icons --> <!-- render the required CSS and JS in the head section --> <!-- loadCSS function header.jsp--> <!-- Google Fonts Include --><!-- loadCSS function fonts.j ...

Core Insights - Novartis (NVS) has proposed the acquisition of Excellergy Inc. to enhance its immunology pipeline, focusing on food allergies and other IgE-mediated diseases [1][9] - The acquisition is valued at up to $2 billion, with expected closure in the second half of 2026, pending regulatory approvals [2] - Exl-111, a key asset in the acquisition, is a next-generation anti-IgE therapy in phase I development, which could expand Novartis' reach in treating various allergic conditions [3][9] Acquisition Details - The deal includes upfront and milestone payments, reinforcing Novartis' commitment to its allergy franchise [2][9] - Exl-111 aims to improve efficacy and dosing convenience, potentially addressing high-value indications such as food allergies and chronic urticaria [3] Strategic Alignment - The acquisition aligns with Novartis' broader immunology ambitions and leverages its expertise in IgE biology, complementing its existing allergy portfolio, which includes Xolair [4] - Novartis is also evaluating remibrutinib for food allergies, further diversifying its treatment options in this area [5] Recent M&A Activity - Novartis has been active in mergers and acquisitions, recently acquiring a PI3Kα inhibitor program from Synnovation Therapeutics, which aligns with its oncology strategy [6][7] - Earlier in the year, Novartis acquired Avidity Biosciences, enhancing its neuromuscular pipeline [8] Market Context - 2026 is a pivotal year for Novartis due to significant patent expirations, particularly for the cardiovascular drug Entresto [8] - Despite challenges from generic competition, Novartis is focusing on growth drivers such as Kisqali, Kesimpta, Pluvicto, and Scemblix to support revenue growth [10]

As filed with the U.S. Securities and Exchange Commission on March 27, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | Cayman Islands | 5122 | Not applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification No.) | Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong +852 2618-9289 ( ...

Core Viewpoint - Maze Therapeutics (MAZE) is being initiated with a "Buy" rating following the release of proof-of-concept data from its phase 2 HORIZON study for the dual-mechanism APOL1 inhibitor MZE829 [2] Company Overview - Maze Therapeutics focuses on developing innovative therapies in the biotech sector, particularly targeting genetic diseases [2] - The company has a model portfolio that includes over 10 small and mid-cap stocks, providing deep analysis for each [2] Study Results - The phase 2 HORIZON study demonstrated promising results for MZE829, which is aimed at treating conditions related to APOL1 [2]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly making false statements and failing to disclose material adverse facts regarding its Phase 3 clinical trial for its product DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [2][5][6]. Company Overview - Soleno Therapeutics, Inc. is a pharmaceutical company based in Redwood City, California, focused on developing therapies for rare diseases. Its only commercial product at the time of the lawsuit was diazoxide choline extended-release tablets (DCCR) [4]. Lawsuit Details - The lawsuit was filed on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, and is pending in the United States District Court for the Northern District of California [2][6]. - Investors have until May 5, 2026, to file for lead plaintiff status [2][8]. Allegations Against Soleno - The complaint alleges that Soleno's executives made materially false and misleading statements regarding the safety and commercial viability of DCCR, including downplaying safety concerns related to excess fluid retention in clinical trial participants [5]. - It is claimed that these misrepresentations led to a lower likelihood of successful commercial adoption and increased risks of adverse events post-launch [5]. Stock Performance - Following the release of financial results on November 4, 2025, and a report by Scorpion Capital that raised concerns about DCCR, Soleno's stock price dropped over 26% due to a decline in patient start forms and increased discontinuations [6][7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. between August 3, 2023, and December 26, 2025, of the April 6, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][7]. - The deadline to move the Court to serve as lead plaintiff is April 6, 2026, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of its Phase III Orbit and Cosmic Studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - Defendants reportedly made overly positive statements about setrusumab's efficacy while concealing material adverse facts, leading to artificially inflated stock prices for Ultragenyx [6].

Market Overview - The Dow Jones Industrial Average fell by 710.40 points (-1.55%) to 45,249.71, with Dow Futures down 685.00 points (-1.48%) at 45,545.00, driven by persistent inflationary pressures revealed in the February Personal Consumption Expenditures (PCE) price index [1] - The decline in the market was influenced by hawkish signals from Federal Reserve officials, leading to a shift in trader expectations regarding near-term interest rate cuts [1] Sector Performance - Significant losses were observed in the healthcare, technology, and financial sectors, with UnitedHealth Group Inc. down 4.06% to $257.36, Salesforce down 3.34%, Amazon down 3.32%, and Cisco Systems down 2.82% [2] - Financial giants also retreated, with JPMorgan Chase & Co. down 2.88% and Visa down 2.78%, alongside Goldman Sachs down 2.68% and IBM down 2.62% [2] Defensive Stocks - Investors shifted towards defensive stocks and energy, with Chevron up 1.81% at $211.56, Coca-Cola up 1.67%, Johnson & Johnson up 1.22%, and Merck up 1.11% [3] - Retail giant Walmart saw an increase of 1.08% to $123.45, while Procter & Gamble was up 0.88%, indicating a flight to quality as investors prioritized stability in Consumer Staples and Energy sectors [3]

Core Viewpoint - Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is recognized as a legitimate company with better performance than perceived, although it is considered speculative [1]. Group 1: Company Overview - Rigel Pharmaceuticals is a biotechnology company focused on developing therapies for hematologic disorders and cancer [3]. - The company provides treatments for conditions such as immune thrombocytopenia and acute myeloid leukemia, and is also working on new inhibitors for autoimmune and inflammatory diseases [3]. Group 2: Investment Perspective - The stock is viewed as a speculative investment opportunity, with a recommendation to consider it as a single speculative buy [1]. - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to Rigel Pharmaceuticals [4].